AC Immune (ACIU) Return on Invested Capital (2022 - 2023)
AC Immune (ACIU) reported Return on Invested Capital of 0.0% for Q4 2023, little changed year-over-year from 0.0% in Q4 2022, and up 30.93% on a QoQ basis from 0.01% in Q3 2023.
AC Immune (ACIU) has 2 years of Return on Invested Capital data on file, last reported at 0.0% in Q4 2023.
- Quarterly Return on Invested Capital changed 0.0% year-over-year to 0.0% in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 0.0% (changed 0.0% YoY) and the FY2024 annual result came in at 0.0%, changed 0.0% from the prior year.
- Return on Invested Capital rose to 0.0% in Q4 2023 per ACIU's latest filing, from 0.01% in the prior quarter.
- Across five years, Return on Invested Capital topped out at 0.0% in Q1 2022 and bottomed at 0.01% in Q3 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -0.01% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 0.00% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -0.01% |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.00% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 0.01% |
| 10 | AC Immune | 325.88 Mn | 211.53 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 0.00% |
| Sep 30, 2023 | -0.01% |
| Jun 30, 2023 | 0.00% |
| Mar 31, 2023 | 0.00% |
| Dec 31, 2022 | 0.00% |
| Sep 30, 2022 | 0.00% |
| Jun 30, 2022 | 0.00% |
| Mar 31, 2022 | 0.00% |